Israeli drug discovery and growth firm Compugen (Nasdaq: CGEN; TASE: CGEN) at the moment introduced modifications in its commercialization cope with AstraZeneca. As a part of the change, the corporate will convert a part of the potential future royalties it will be entitled to into quick money.
Compugen will obtain $65 million instantly and one other $25 million if it meets a comparatively shut milestone, and this money needs to be sufficient to finance the corporate’s operations till 2029. In return, if the product is profitable, will probably be entitled to obtain barely decrease royalties from AstraZeneca than stipulated within the unique settlement.
Following the announcement, Compugen shares are actually rising by about 16% on the Tel Aviv Inventory Trade (TASE).
Promising product
Compugen is growing medicine for the remedy of most cancers, particularly most cancers remedy utilizing the immune system (immunotherapy), based mostly on a computational biology system that it has been growing for the reason that Nineties. It doesn’t but have a gradual income stream from its merchandise, however over time it has signed quite a few strategic agreements with pharmaceutical firms, which fund and conduct trials of its merchandise with the purpose of selling them later and sharing the royalties.
The product that Compugen transferred to AstraZeneca can be thought-about a promising product by the UK biopharmaceutical firm, and it’s conducting 11 medical trials on it in numerous kinds of most cancers, together with lung most cancers, gastrointestinal most cancers and endometrial most cancers.
That is an antibody that concurrently assaults each a well-liked goal within the discipline of immunotherapy, PD1, and one other goal for which Compugen competes with a small variety of different firms, TIGIT. Compugen believes that the TIGIT part of the product, which it developed itself, is the very best within the class.
Compugen stresses that it retains many of the future royalties from the product. It’s going to obtain $195 million for assembly numerous milestones, plus mid-single-digit income royalties. $25 million of the potential $195 million was superior underneath the present deal, which can now be paid if and when the product is submitted for approval by the FDA.
Beneath the settlement signed in 2018, Compugen was alleged to obtain as much as $200 million in milestone funds in addition to royalties from the product that enhance based mostly on success. In different phrases, the principle part it’s giving up might be the excessive royalties within the occasion of a really main success. Compugen has already obtained $40 million in money as a part of the deal round this product.
Extra royalties on the way in which?
Compugen additionally has one other main strategic settlement with Gilead Sciences, through which it has obtained $60 million, and it might obtain a further $30 million at an upcoming milestone and as much as $758 million in milestone funds and royalties within the occasion of the product’s success.
As well as, the companyu has two of its personal standalone merchandise in medical trials and an earlier product pipeline. The quantity raised on this deal is anticipated to permit it to proceed growing primarily its standalone merchandise.
Compugen had $86.1 million in money on the finish of the third quarter, which the corporate mentioned would have been sufficient to final till mid-2027. This was previous to signing the present deal.
This transfer is the primary important enterprise transfer by incoming CEO Dr. Eran Ophir, who changed Dr. Anat Cohen-Dayag in Might, after she served as CEO of Compugen for about 15 years. Cohen-Dayag is presently the corporate’s chairperson.
Printed by Globes, Israel enterprise information – en.globes.co.il – on December 17, 2025.
© Copyright of Globes Writer Itonut (1983) Ltd., 2025.
